Vistagen , a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called ...

It's a really rare disease. It's basically one in a million,” says Onyx Middleton's neurologist Dr. Varun Kannan ...

The global Alzheimer’s therapeutics market revenue was valued at US$ 6.5 billion in 2021 and is projected to reach US$ 13.6 billion by 2031. The market will register a CAGR (Compound Annual Growth ...

In this important study, the authors use computational modeling to explore how rapid learning can be reconciled with the accumulation of stable memories in the olfactory bulb, where adult neurogenesis ...

A Cleveland Clinic psychiatrist explains how ketamine therapy is transforming depression treatment—and why it works when ...

Ultrasound therapy is emerging as a potential treatment for Alzheimer’s disease. It uses ultrasound to open the blood-brain ...

Ask a healthcare professional (HCP) to name a psychiatric medicine and chances are they’ll say a brand approved at least 10 ...

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

Here, we explored how NMDARs signal in tLTD. We found that, regardless of frequency, L5 PC→PC tLTD relies on the non-ionotropic preNMDAR signaling pathway mediated by JNK2, which helps to resolve the ...

Users say they feel relief from burning feet, numb fingers, nerve zaps, and leg cramps within weeks. More impressively, many ...

Discover how the brain's most abundant neurotransmitter, glutamate, is revolutionizing psychiatry and offering new hope for ...

Enter psychedelics like ketamine, psilocybin, and MDMA, which are being explored as tools to access and process these buried experiences. They offer a non-linear, ego-dissolving space where ...